What are the primary drivers of Eli Lilly's significant revenue growth in the first half of 2026?

The primary drivers of Eli Lilly's substantial revenue growth in the first half of 2026 are the strong performance and increased volume of its cardiometabolic health products, specifically Mounjaro and Zepbound. These products accounted for 65% of total revenue for the six months ended June 30, 2026, highlighting their critical role in the company's financial success. The company also saw growth in collaboration and other revenue, including milestones related to Jardiance.

How are the recent acquisitions impacting Eli Lilly's financial results?

Eli Lilly has made significant investments in business development through acquisitions, including Kelonia, Centessa, and Ventyx in the first half of 2026, totaling $13.3 billion. These acquisitions are reflected in a substantial increase in acquired in-process research and development (IPR&D) charges, which rose to $3.4 billion for the six months ended June 30, 2026. Additionally, asset impairment, restructuring, and other special charges increased due to acquisition and integration costs. While these increase short-term expenses, they are strategically aimed at enhancing the company's product pipeline and driving long-term growth.

What is the company's financial position regarding debt and liquidity?

Eli Lilly's financial position remains robust. Cash and cash equivalents increased to $9.0 billion as of June 30, 2026, up from $7.3 billion at the end of 2025. The company issued $9.0 billion in long-term debt in May 2026, primarily to fund acquisitions and for general corporate purposes, which increased its total debt to $54.9 billion. Despite the increase in debt, the company has ample liquidity with significant credit facilities available, and its operating cash flow generation is strong, indicating it can meet its financial obligations and capital requirements.

What are the key developments in Eli Lilly's clinical pipeline and how do they impact the business?

Eli Lilly is actively advancing its clinical development pipeline, with several promising updates. Key developments include the FDA approval of orforglipron (Foundayo) for obesity and submission for type 2 diabetes, a positive opinion for insulin efsitora alfa in the EU for type 2 diabetes, and initiation of Phase 3 trials for baricitinib (type 1 diabetes), eloralintide (obesity, OSA, OA pain), and brenipatide (major depressive disorder). Retatrutide's Phase 3 trials for obesity and type 2 diabetes met their primary endpoints. These advancements are crucial for future revenue streams, although they also contribute to increased R&D expenses, which grew by 21% for the first six months of 2026.

LLY 10-Q Quarterly Report Q2 FY2026 — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-Q filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.

Eli Lilly and Company (LLY) reported a strong financial performance for the six months ended June 30, 2026, with revenue soaring by 51% to $42.8 billion^a and net income increasing by 72% to $14.5 billion, driven by significant growth in its cardiometabolic health portfolio, particularly Mounjaro and Zepbound.

Diluted earnings per share (EPS) also saw a substantial jump of 73% to $16.19^b. The company's strategic investments in research and development, alongside significant acquisitions, are fueling future growth, although these also contribute to increased expenses. The substantial increase in acquired in-process research and development (IPR&D) and asset impairment, restructuring, and other special charges highlight the active business development strategy.

Despite these investments and higher operating expenses, Lilly demonstrated robust profitability and expanding gross margins. Financially, Lilly maintained a strong liquidity position, with cash and cash equivalents growing to $9.0 billion^c.

The company also strategically managed its debt, issuing $9.0 billion^d in long-term debt to fund acquisitions and general corporate purposes. Shareholder returns remain a focus, with $3.1 billion in dividends paid and $4.0 billion in share repurchases during the period.

02—Key points

Key Highlights

Revenue surged 51% year-over-year to $42.8 billion for the six months ended June 30, 2026, primarily driven by Mounjaro and Zepbound.
Net income increased by 72% to $14.5 billion for the same period, reflecting strong revenue growth and improved gross margins.
Diluted EPS rose 73% to $16.19 for the six months ended June 30, 2026, indicating enhanced profitability on a per-share basis.
The company completed significant acquisitions in the first half of 2026, including Kelonia, Centessa, and Ventyx, totaling $13.3 billion in business development activity, which are expected to bolster the product pipeline.
Acquired in-process R&D (IPR&D) expenses saw a substantial increase, reaching $3.4 billion for the six months ended June 30, 2026, reflecting investments in new drug development.
Total debt increased by $12.4 billion to $54.9 billion as of June 30, 2026, largely due to new long-term debt issuances to fund acquisitions.
The company continues to return capital to shareholders, paying $3.1 billion in dividends and repurchasing $4.0 billion in stock during the first six months of 2026.

03—Questions

Frequently Asked Questions

What are the primary drivers of Eli Lilly's significant revenue growth in the first half of 2026?
The primary drivers of Eli Lilly's substantial revenue growth in the first half of 2026 are the strong performance and increased volume of its cardiometabolic health products, specifically Mounjaro and Zepbound. These products accounted for 65% of total revenue for the six months ended June 30, 2026, highlighting their critical role in the company's financial success. The company also saw growth in collaboration and other revenue, including milestones related to Jardiance.
How are the recent acquisitions impacting Eli Lilly's financial results?
Eli Lilly has made significant investments in business development through acquisitions, including Kelonia, Centessa, and Ventyx in the first half of 2026, totaling $13.3 billion. These acquisitions are reflected in a substantial increase in acquired in-process research and development (IPR&D) charges, which rose to $3.4 billion for the six months ended June 30, 2026. Additionally, asset impairment, restructuring, and other special charges increased due to acquisition and integration costs. While these increase short-term expenses, they are strategically aimed at enhancing the company's product pipeline and driving long-term growth.
What is the company's financial position regarding debt and liquidity?
Eli Lilly's financial position remains robust. Cash and cash equivalents increased to $9.0 billion as of June 30, 2026, up from $7.3 billion at the end of 2025. The company issued $9.0 billion in long-term debt in May 2026, primarily to fund acquisitions and for general corporate purposes, which increased its total debt to $54.9 billion. Despite the increase in debt, the company has ample liquidity with significant credit facilities available, and its operating cash flow generation is strong, indicating it can meet its financial obligations and capital requirements.
What are the key developments in Eli Lilly's clinical pipeline and how do they impact the business?
Eli Lilly is actively advancing its clinical development pipeline, with several promising updates. Key developments include the FDA approval of orforglipron (Foundayo) for obesity and submission for type 2 diabetes, a positive opinion for insulin efsitora alfa in the EU for type 2 diabetes, and initiation of Phase 3 trials for baricitinib (type 1 diabetes), eloralintide (obesity, OSA, OA pain), and brenipatide (major depressive disorder). Retatrutide's Phase 3 trials for obesity and type 2 diabetes met their primary endpoints. These advancements are crucial for future revenue streams, although they also contribute to increased R&D expenses, which grew by 21% for the first six months of 2026.

04—Continue

← View all 10-Q filings